Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01319591 · ClinicalTrials.gov registry record
Comparison of Creatinine Clearance Calculation for Estimation of GFR in Patients Receiving HD Methotrexate
A clinical trial, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- 40
- Enrollment target
NCT01319591 is a clinical trial that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 40 participants.
The verdict
NCT01319591 has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to compare different estimates of calculating creatinine clearance by mathematical formula and compare them to creatinine clearance based on a timed urine collection in patients who received high-dose methotrexate for the treatment of primary CNS lymphoma or CNS involvement of systemic lymphoma.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2011-03 |
| Est. Completion | 2017-09-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01319591
The ClinicalTrials.gov registry entry for NCT01319591 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01319591 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01319591 about?
NCT01319591 is a clinical study titled "Comparison of Creatinine Clearance Calculation for Estimation of GFR in Patients Receiving HD Methotrexate". The purpose of this study is to compare different estimates of calculating creatinine clearance by mathematical formula and compare them to creatinine clearance based on a timed urine collection in patients who received high-dose methotrexate for the treatment of primary CNS lymphoma or CNS involvem...
What is the current status of trial NCT01319591?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2011-03. Estimated completion is 2017-09-01.
Who is sponsoring clinical trial NCT01319591?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.